Metabolic therapy developer Axcella Health has priced its shares at $20 each in an offering that enabled Nestlé Health Science to exit.

Axcella Health, a US-based metabolic drug developer that counts food and nutritional product supplier Nestlé as an investor, has gone public in a $71.4m initial public offering. The company issued approximately 3.57 million shares on the Nasdaq Global Market priced at the bottom of the $20 to $22 range it set late last month. Undisclosed…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.